- Home
- JYNT vs LRMR Comparison
JYNT vs LRMR Comparison
Compare JYNT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- LRMR
- Stock Information
- Founded
- JYNT 2010
- LRMR N/A
- Country
- JYNT United States
- LRMR United States
- Employees
- JYNT N/A
- LRMR N/A
- Industry
- JYNT Multi-Sector Companies
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- LRMR Health Care
- Exchange
- JYNT Nasdaq
- LRMR Nasdaq
- Market Cap
- JYNT 170.1M
- LRMR 183.8M
- IPO Year
- JYNT 2014
- LRMR N/A
- Fundamental
- Price
- JYNT $9.99
- LRMR $2.12
- Analyst Decision
- JYNT Strong Buy
- LRMR Strong Buy
- Analyst Count
- JYNT 2
- LRMR 9
- Target Price
- JYNT $15.50
- LRMR $19.00
- AVG Volume (30 Days)
- JYNT 62.5K
- LRMR 1.4M
- Earning Date
- JYNT 05-08-2025
- LRMR 04-30-2025
- Dividend Yield
- JYNT N/A
- LRMR N/A
- EPS Growth
- JYNT N/A
- LRMR N/A
- EPS
- JYNT N/A
- LRMR N/A
- Revenue
- JYNT $52,789,479.00
- LRMR N/A
- Revenue This Year
- JYNT $10.88
- LRMR N/A
- Revenue Next Year
- JYNT $12.11
- LRMR N/A
- P/E Ratio
- JYNT N/A
- LRMR N/A
- Revenue Growth
- JYNT N/A
- LRMR N/A
- 52 Week Low
- JYNT $9.58
- LRMR $1.61
- 52 Week High
- JYNT $17.82
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- JYNT 44.27
- LRMR 44.72
- Support Level
- JYNT $9.61
- LRMR $2.03
- Resistance Level
- JYNT $10.60
- LRMR $2.33
- Average True Range (ATR)
- JYNT 0.52
- LRMR 0.30
- MACD
- JYNT 0.06
- LRMR -0.01
- Stochastic Oscillator
- JYNT 29.23
- LRMR 11.21
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.